Drug Profile
Vanutide cridificar
Alternative Names: AAC 001; ACC-001; Active beta-amyloid immunotherapeutic conjugate; Aβ immunotherapeutic conjugate; CRM 197; Peptide-CRM Conjugate; PF-05236806; PF-5236806Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Elan Corporation; Wyeth
- Developer JANSSEN Alzheimer Immunotherapy; Pfizer
- Class Alzheimer vaccines; Antidementias; Carrier proteins; Drug conjugates; Immunoconjugates; Peptide fragments
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Alzheimer's disease
Most Recent Events
- 01 Mar 2016 Pfizer terminates a phase II long-term extension trial in Alzheimer's disease in USA (NCT00960531)
- 01 Feb 2014 Pfizer and JANSSEN Alzheimer Immunotherapy complete a phase II trial in Alzheimer's disease in USA (NCT01227564)
- 01 Feb 2014 Pfizer and JANSSEN Alzheimer Immunotherapy complete a phase II ACCTION trial in Alzheimer's disease in USA (NCT01284387)